Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical (ISRG) reported third-quarter 2026 revenue of $3,048.7 million, up 22% from $2,505.1 million a year earlier. Approximately 906,000 da Vinci procedures were performed, up 14%, and approximately 49,700 Ion procedures, up 31%. Operating income was $592.6 million, down 22% from $759.7 million, while net income attributable to Intuitive was $522.8 million versus $704.4 million.
Intuitive repurchased 7.8 million shares for an aggregate cost of $2.94 billion during the quarter. Cash, cash equivalents, and investments totaled $6.80 billion as of September 30, 2026, compared with $9.03 billion as of December 31, 2025. On March 1, 2026, Intuitive acquired da Vinci and Ion distribution businesses previously operated by ab medica, Abex, Excelencia Robótica, and their affiliates for approximately $533.1 million in cash, net of the effective settlement of existing receivables of $32.6 million. It assumed direct distribution responsibilities for Italy, Spain, Portugal, Malta, San Marino, and associated territories.
Intuitive Surgical (ISRG) reported third-quarter 2026 revenue of $3.05 billion, up 22% from $2.51 billion a year earlier. Worldwide da Vinci and Ion procedures grew approximately 15%.
GAAP net income attributable to Intuitive was $523 million, or $1.49 per diluted share, versus $704 million and $1.95 a year earlier; non-GAAP net income was $1.05 billion, or $3.00 per diluted share, versus $867 million and $2.40. GAAP results included a $450 million pre-tax charge tied to the company’s settlement of previously disclosed antitrust class-action litigation. The agreement provides for a one-time $450 million payment and mutually agreed injunctive relief, without admission of liability or wrongdoing, and is subject to preliminary and final Court approval.
For 2026, Intuitive expects da Vinci procedure growth of approximately 14% to 15%, non-GAAP gross profit margin of 68.7% to 69.3%, and non-GAAP operating expense growth of 11% to 13%. The margin range includes an estimated tariff impact of 0.9% of revenue, excluding recognized tariff refunds, and assumes current tariffs remain in place through year-end. Intuitive repurchased 7.8 million shares for $2.94 billion in Q3.
Patricia L. Wadors, Intuitive Surgical’s SVP and Chief Human Resources Officer, had 2,140 restricted stock units convert into 2,140 common shares on October 10, 2026. Of those shares, 1,062 were withheld to cover tax-withholding obligations at $423.96 per share; net shares were deposited into the holder’s account. Her reported post-transaction RSU balance was 4,279.
Intuitive Surgical (ISRG) executive vice president Gary Loeb reported conversion of 2,612 restricted stock units into 2,612 common shares on October 10, 2026. 1,296 shares were withheld to cover tax withholding obligations at $423.96 per share, and the net shares were deposited into the holder’s account. The RSUs vest 25% per year over four years, beginning on the grant’s first anniversary; no Rule 10b5-1 plan is reported.
INTUITIVE SURGICAL INC (ISRG) executive Fredrik Widman, VP Corporate Controller, reported an exercise-and-sell transaction on September 15, 2026 under a Rule 10b5-1 trading plan. He exercised options for 546 and 543 shares of common stock and sold the corresponding 1,089 shares on the same day.
Intuitive Surgical, Inc. (ISRG) is the issuer in a Rule 144 notice filed for planned sales of its common stock by officer Fredrik Carl Widman. The notice covers the potential sale of 2,178 shares of Intuitive Surgical common stock, to be sold through Morgan Stanley Smith Barney LLC on or after September 15, 2026, in connection with an exercise of stock options for cash. The filing lists an aggregate market value of $823,153.32 for the securities covered.
INTUITIVE SURGICAL INC (ISRG) executive Mark Brosius, EVP & Chief Manufacturing and Supply Chain, reported selling a total of 48 shares of common stock in open market or private transactions on September 10 and 11, 2026, under a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
INTUITIVE SURGICAL INC (ISRG) reported that executive vice president and chief manufacturing and supply chain officer Mark Brosius sold a total of 69 shares of common stock in two transactions. On September 8, 2026 he sold 46 shares at $361.23 per share, and on September 9, 2026 he sold 23 shares at $350.20 per share. Both sales were made in open market or private transactions pursuant to a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
INTUITIVE SURGICAL INC (ISRG) received a Rule 144 notice covering a planned sale of its common stock by officer Mark Preston Brosius. The notice relates to 694 shares of common stock held in an account at Morgan Stanley Smith Barney, with an aggregate market value of $254,489.80 as of September 8, 2026.
The shares derive from performance stock units awarded by the issuer, with a grant date of February 28, 2026. The notice also lists prior Rule 10b5-1 plan sales of ISRG common stock by Brosius over the past three months in small increments.
INTUITIVE SURGICAL INC (ISRG) reported that executive vice president and Chief Manufacturing and Supply Chain officer Mark Brosius sold a total of 154 shares of common stock in two open-market transactions on August 20 and 21, 2026, at prices of $396.37 and $375.57 per share. Both sales were made pursuant to a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and is disclosed as expiring on February 14, 2027.